Todd Hoopman, MD
Pulmonary Disease · Coeur D Alene, IDNPI 1275663361
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 77.4% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2024 at $30,619 and has fallen 66.8% since, to $10,176 in 2025. Among pulmonary disease clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 187 payments — averaging $408.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$59K
- Covidien LP$15K
- AstraZeneca$587
- GSK$202
- Cytovale, Inc.$147
- Genentech USA, Inc.$146
- plus $995 from 21 others
What the payments were for
- Consulting fees$25,16933%
- Speaking & faculty fees$43,98458%
- Travel & lodging$3,6525%
- Food & beverage$3,5665%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 70 | $59,182 |
| Covidien LP | 19 | $15,164 |
| AstraZeneca | 23 | $587 |
| GSK | 20 | $202 |
| Cytovale, Inc. | 1 | $147 |
| Genentech USA, Inc. | 7 | $146 |
| Pulmonx Corporation | 2 | $145 |
| Boehringer Ingelheim | 6 | $112 |
| Johnson & Johnson | 5 | $82 |
| Insmed, Inc. | 2 | $75 |
| Grifols USA, LLC | 4 | $64 |
| Merck | 4 | $59 |
| Gilead | 3 | $55 |
| Philips North America LLC | 3 | $49 |
| Bayer | 2 | $43 |
| United Therapeutics Corporation | 2 | $42 |
| Actelion Pharmaceuticals US, Inc. | 2 | $41 |
| Advanced Respiratory, Inc | 2 | $35 |
| Mallinckrodt Enterprises LLC | 1 | $33 |
| Mylan Specialty L.p. | 2 | $30 |
| Electromed, Inc. | 1 | $29 |
| Shire North American Group Inc | 1 | $20 |
| Sanofi | 1 | $19 |
| AbbVie | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Pfizer | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUMISITE$30,286
- superDimension$14,971
- CHARTIS CATHETER$137
- ZEPHYR DELIVERY CATHETER$137
- ZEPHYR ENDOBRONCHIAL VALVE$137
- PULMONX CHARTIS TABLET CONSOLE$137
- TAGRISSO$105
How this compares
$76,422 in reported general payments places this provider in the 95th percentile of 57 pulmonary disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 33 | $421,562 |
| AdempasRiociguat | 21 | $290,528 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 322 | $278,645 |
| Fasenra PenBenralizumab | 32 | $166,978 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 180 | $135,205 |
| Breo ElliptaFluticasone/Vilanterol | 155 | $74,352 |
| Spiriva RespimatTiotropium Bromide | 59 | $45,787 |
| Spiriva HandihalerTiotropium Bromide | 42 | $32,505 |
| EliquisApixaban | 11 | $19,125 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $19,009 |
| Pirfenidone | 12 | $18,933 |
| SymbicortBudesonide/Formoterol Fumarate | 52 | $17,012 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $14,118 |
| BreynaBudesonide/Formoterol Fumarate | 55 | $10,208 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $9,734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $112 | $491,201126 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $202 | $377,920520 claims |
| BayerAdempas | $43 | $290,52821 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Daliresp, Bevespi Aerosphere | $587 | $162,339256 claims |
| PfizerEliquis | $16 | $19,12511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 57 pulmonary disease providers in Idaho.
Other pulmonary disease in Coeur D Alene
- Robert ScogginsCoeur D Alene$2K
- Jeannette Zinggeler BergCoeur D Alene$1K
- Amanda LiggettCoeur D Alene$977
- Kevin ChangCoeur D Alene$905
- Forrest JespersenCoeur D Alene$839
- David YorkCoeur D Alene$757
- Chad BrizendineCoeur D Alene$268
- Elizabeth HankinsonCoeur D Alene$0
- Allen SalemIdaho Falls$44K
- Mark RasmusBoise$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.